Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 51

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 8
Chunk 51
---
 three months ended June 30, 2025, primarily due to a $30,789 reduction in insurance costs. This decrease was partially offset
by a $25,853 increase in clinical trial-related expenses, with the remaining variance attributable to a mix of smaller increases and decreases
across multiple categories that netted to an overall decline.

Other (Expense) Income, Net

We recorded other income of $30,532 for the three
months ended June 30, 2025 compared to other income of $49,418 for the three months ended June 30, 2024. Other income in both periods
was primarily interest income.

Net Loss

As a result of the changes in expenses noted above,
our net loss decreased to $1,761,858 in the three months ended June 30, 2025 from $2,571,440 in the three months ended June 30, 2024.

Basic and diluted loss attributable to common stockholders
was ($0.85) for the three months ended June 30, 2025, compared to ($2.76) for the three-month period ended June 30, 2024.

 20 

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2025, we had a cash balance of $3,765,154
and working capital of $2,423,421. This compares to a cash balance of $5,501,261 and working capital of $4,050,514 at March 31, 2025.

We do not expect our existing cash as of June 30,
2025, to be sufficient to fund our operations for at least twelve months from the issuance date of these financial statements.

As we expand our activities, our overhead costs to
support personnel, laboratory materials and infrastructure will increase and significant additional financing must be obtained to provide
a sufficient source of operating capital. Should the financing we require to sustain our working capital needs be unavailable to us on
reasonable terms, if at all, when we require it, we may be unable to support our research and our planned clinical trials. The failure
to implement our research and clinical trials would have a material adverse effect on our ability to conduct planned clinical trials and
commercialize our products.

Future capital requirements will depend upon many
factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs, the time and
costs associated with intellectual property protection and enforcement,